Crescendo – Proprietary, robust, and highly efficient transgenic VH domain technology

DEVELOPING HUMABODY^®
THERAPEUTICS

Crescendo Biologics’ second oncology-targeted Humabody® licensed by Takeda 23 July 2019

Crescendo Biologics to present preclinical data on its lead Humabody® candidate, CB307, at the Cell Engager Therapeutics Summit 2019 24 June 2019

Crescendo Biologics Announces Prestigious Academic Research Collaborations 31 May 2019

Crescendo Biologics develops potent, multi-functional Humabody^® therapeutics with a focus on novel targeted T-cell engagement.

Using our proprietary transgenic mouse platform, we have created a tumour-targeted T-cell engager mechanism capable of activating T-cells only in the tumour microenvironment. Our ability to configure unique therapeutic formats allows Humabodies to engage targets in ways that generates new biology through novel target engagement.

Our transgenic V_H platform enables us to create an almost limitless number of mono- and multi-functional (Multibody^®) constructs capable of engaging therapeutically valuable targets in a way that is fundamentally different to whole antibodies.

Using our formatting and development expertise, we produce highly potent optimally configured therapeutics by using differentiated approaches such as:

combinatorial specificity/functionality
bi-paratopic targeting
tuneable internalisation
extended half-life.

Our unique tumour-targeted T-cell engagers deliver safe, highly potent cancer killing by activating only tumour-specific T-cells within the tumour microenvironment. Their superior biodistribution through minimal size, enhanced tissue penetration and tumour accumulation has the potential to deliver greatly improved therapeutic index through both enhanced safety and potency.